Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement f

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make...

Related Keywords

Japan ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Osaka ,American ,Ann Hematol ,Dineshv Patel ,Julie Kim ,Be Protagonist Co ,Takeda Pharmaceutical Company Limited ,Drug Administration ,Exchange Commission ,Takeda Pharmaceuticals United Statesa Inc ,European Medicines Agency ,Protagonist Therapeutics Inc ,American Society Of Hematology ,Nasdaq ,Japan Ministry Of Health ,Us Co ,Takeda Will Be Protagonist ,Commercialization Partner With ,With Exclusive Ex U ,Commercialize Rusfertide ,Polycythemia Vera ,Will Make ,Upfront Payment ,Combines Protagonist ,Commercial Expertise ,Plus Year Legacy ,Driving Innovation Within ,Rare Hematology ,Host Conference Call ,Webcast Today ,Protagonist Therapeutics ,American Society ,Orphan Drug Designation ,Fast Track ,Rare Pediatric Disease ,Rare Pediatric Disease Voucher ,Specific Populations ,Takeda Pharmaceuticals United Statesa ,Prescribing Information ,Leuk Lymphoma ,Englj Med ,Annual Report ,Therapeutics Cautionary Note ,Private Securities Litigation Reform Act ,